- Home
- REBN vs IMNN Comparison
REBN vs IMNN Comparison
Compare REBN & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- IMNN
- Stock Information
- Founded
- REBN 2015
- IMNN 1982
- Country
- REBN United States
- IMNN United States
- Employees
- REBN N/A
- IMNN N/A
- Industry
- REBN Restaurants
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- IMNN Health Care
- Exchange
- REBN Nasdaq
- IMNN Nasdaq
- Market Cap
- REBN 13.5M
- IMNN 12.1M
- IPO Year
- REBN 2022
- IMNN 1985
- Fundamental
- Price
- REBN $2.46
- IMNN $1.55
- Analyst Decision
- REBN
- IMNN Buy
- Analyst Count
- REBN 0
- IMNN 2
- Target Price
- REBN N/A
- IMNN $14.00
- AVG Volume (30 Days)
- REBN 61.1K
- IMNN 31.3M
- Earning Date
- REBN 05-20-2025
- IMNN 05-12-2025
- Dividend Yield
- REBN N/A
- IMNN N/A
- EPS Growth
- REBN N/A
- IMNN N/A
- EPS
- REBN N/A
- IMNN N/A
- Revenue
- REBN $6,103,732.00
- IMNN N/A
- Revenue This Year
- REBN $335.98
- IMNN N/A
- Revenue Next Year
- REBN N/A
- IMNN N/A
- P/E Ratio
- REBN N/A
- IMNN N/A
- Revenue Growth
- REBN 3.38
- IMNN N/A
- 52 Week Low
- REBN $1.03
- IMNN $0.37
- 52 Week High
- REBN $8.80
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- REBN 36.84
- IMNN 53.15
- Support Level
- REBN $2.46
- IMNN $1.40
- Resistance Level
- REBN $2.78
- IMNN $3.16
- Average True Range (ATR)
- REBN 0.18
- IMNN 0.51
- MACD
- REBN -0.01
- IMNN 0.03
- Stochastic Oscillator
- REBN 7.50
- IMNN 40.14
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).